Emerging alternatives Retatrutide is a triple receptor agonist (GIP, GLP-1, and glucagon) currently in clinical trials that has shown even greater weight loss than tirzepatide in early data
Heres a closer look at the differences between them: GLP #1 Increases insulin production Slows gastric emptying Reduces appetite and calorie intake Helps with sugar cravings Promotes significant weight loss GLp #2 Dual GIP and GLP-1 receptor agonist Enhances insulin secretion Potential for more weight loss compared to GLP #1 Potentially better for glycemic control For those interested in the cutting-edge benefits of GLP-1s, our clinic in Centennial, CO, offers this innovative treatment
According to the researchers, the overall rate of NAION among the groups was low, but it was higher for those in the semaglutide group
The broader point the article makes, that weight indications trailed diabetes by a long way, still stands
* Vitamin D Vitamin D is central to healthy bones and influences cell growth and immune function